• No products in the list

EGFR StripAssay

Short description

The ViennaLab EGFR XL StripAssay® is a state-of-the-art diagnostic tool specifically designed for non-small cell lung cancer (NSCLC) treatment optimization. This assay identifies 30 key EGFR mutations, enabling clinicians to make informed decisions on the administration of tyrosine kinase inhibitors (TKIs). Through a reliable three-step process—DNA isolation, PCR amplification, and reverse-hybridization—the test provides an accurate mutational profile. It serves as an invaluable aid in patient stratification, guiding the use of first-, second-, or third-generation TKIs based on the detected EGFR mutations. Its comprehensive coverage and clinical reliability make it an essential asset in personalized oncology.

Product highlights

  • Precise Identification
  • Broad Coverage
  • Clinically Reliable
  • Patient Stratification
  • TKI Optimization
  • Diagnostic Efficiency

Ask for a quote

EGFR StripAssay



Instructions for Use

Brochure StripAssays


For any missing information or if you require additional details, please do not hesitate to contact us. 

Specifications of the EGFR StripAssay

The EGFR XL StripAssay® by ViennaLab—A Paradigm Shift in NSCLC Treatment Algorithms


Targeted therapies have rapidly gained prominence in the complex landscape of oncological treatment, necessitating advanced diagnostic tools for informed decision-making. One such critical diagnostic instrument is ViennaLab’s EGFR XL StripAssay®, a specialized assay designed to identify 30 clinically pertinent mutations in the epidermal growth factor receptor (EGFR) gene for non-small cell lung cancer (NSCLC).

EGFR and Its Clinical Significance in NSCLC

Constituting approximately 85% of all lung cancers, NSCLC is notably influenced by the presence or absence of mutations in the EGFR gene. These mutations serve as predictive markers for the therapeutic efficacy of tyrosine kinase inhibitors (TKIs). For instance, patients harboring EGFR ‘activating mutations’ may derive clinical benefits from first-, second-, or third-generation TKIs. Conversely, the presence of ‘resistance mutations’ such as EGFR T790M necessitates the use of specialized third-generation TKIs.

Assay Methodology and Clinical Utility

The EGFR XL StripAssay® employs a tripartite methodology consisting of DNA isolation, PCR amplification using biotinylated primers, and reverse-hybridization. The resultant amplification products are hybridized to a test strip containing allele-specific oligonucleotide probes. These probes are visualized through a detection mechanism involving streptavidin-alkaline phosphatase and color substrates, offering a robust and clinically-reliable diagnostic result.

The assay provides broad coverage of the EGFR gene, particularly mutations within exons 18/19/20/21, thereby enabling clinicians to make informed decisions on therapeutic regimens. It plays a pivotal role in patient stratification, as TKI therapy’s efficacy varies depending on the EGFR mutational status.

Clinical Implications and Therapeutic Choices

First-line TKIs such as erlotinib and gefitinib have shown marked efficacy in NSCLC patients carrying EGFR ‘activating mutations.’ However, the occurrence of ‘resistance mutations’ like T790M signals the inadequacy of first-line TKIs, prompting a reevaluation of therapeutic strategies. Hence, the precise identification of EGFR mutations through the EGFR XL StripAssay® is of paramount importance for tailoring individualized treatment plans and avoiding unnecessary adverse effects from ineffective therapies.


ViennaLab’s EGFR XL StripAssay® represents an invaluable tool in the evolving arena of personalized oncology. It not only aids in the stratification of patients for TKI therapy but also optimizes therapeutic choices, thereby holding the potential for significantly improved clinical outcomes. By contributing to targeted and effective treatment regimens, the EGFR XL StripAssay® is positioned as an indispensable asset in modern oncology.

Components of the EGFR StripAssay
  • Amplification Mix A (yellow cap)
  • Amplification Mix B (green cap)
  • Taq Dilution Buffer (transparent cap)
  • Taq DNA Polymerase (5 U/µl) (red cap)
  • DNAT (blue cap)
  • Typing Trays
  • Test Strips
  • Hybridization Buffer (white cap)
  • Wash Solution A (white cap)
  • Conjugate Solution
  • Wash Solution B
  • Color Developer
  • Collector™ Sheet

Explore Related Items